Fig. 5
From: ERO1α is a novel endogenous marker of hypoxia in human cancer cell lines
Colocalisation of ERO1α and pimonidazole at hypoxic sites in tumour xenografts. HCT116 cells were inoculated into nude mice; 28 days later, pimonidazole was intravenously injected. Tumours (n = 4) were excised and subjected to immunostaining. Representative images are shown. a Immunohistological staining using 3,3′-diaminobenzidine (DAB) as chromogenic substrate. Scale bar: 500 μm (b) Fluorescent immunostaining of ERO1α (green) and pimonidazole (red). 4′,6-Diamidino-2-phenylindole (DAPI, blue) was used to localise the nuclei. Scale bar: 40 μm. c Localisation of ERO1α, pimonidazole, and CA9 in various cancer cell line (HeLa, HT29, A549, and MIA PaCa2) tumour xenografts. Representative tissue photographs are shown. Scale bar: 1 mm